Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. - Wikidata - wikimedia - TriplyDB

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

http://www.wikidata.org/entity/Q41624982

about

Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

P2860

Q26786160-BEBD1044-FBB6-413B-80B9-06D1014AA39F Q36092829-14CB7323-2F21-42FB-AE63-80A07E339167 Q37536769-FF7BC74B-4A79-41E9-B196-73779224C88B Q37657236-A1C0E023-06A1-4F43-9629-79E706049AF5 Q38543085-DF5970EB-C085-4768-A487-F67F80C17C00 Q38906250-C0AC3888-6949-4210-9FE6-030AE4BDE60C Q38907399-EAE1E75E-0E44-4B3F-BFBC-9B6B8F96E3C0 Q42370353-34574489-D9DE-47E6-9F29-CC1B7580366A Q47149978-A1FD9487-BF5E-4588-8498-D424666606E8 Q55101776-8FA5C951-2FED-458D-B776-71C244003A75

P2860

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

http://www.wikidata.org/entity/Q41624982

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prognostic significance of hos ...... treated with targeted therapy.

@en

type

label

Prognostic significance of hos ...... treated with targeted therapy.

@en

prefLabel

Prognostic significance of hos ...... treated with targeted therapy.

@en

P1433

Q41624982-20D570EF-ACAC-4B71-8114-F7D6D0C73F19

P1476

Q41624982-B019D639-03A4-4979-B24B-8C93B0EE6D99

P2093

Q41624982-05DEE2B5-BE5E-461B-A845-A4FF6C386C91

Q41624982-06CB7DE0-8B2D-4CA2-A442-BF4C279C7DE5

Q41624982-1F9F8DE1-D2A8-4294-B421-9D8F51641A56

Q41624982-2140AD3F-E675-4D26-BC05-48665202A4F4

Q41624982-254DDB50-D618-40D0-B4D6-743916A56B22

Q41624982-6F06DB82-F963-4A1E-BEB2-05C6A2FB4B17

Q41624982-6FECF9B1-A80A-4451-B85A-7A4C8B33CC0B

Q41624982-7A8D444F-6930-4005-8282-20C19AAC7FF8

Q41624982-A4788841-E700-4693-A2CE-3047EE1710A4

Q41624982-E3073430-F845-4B2B-8973-E916CFF669B2

P2860

Q41624982-03E35975-D9F0-4E31-8B2D-0A82E25DCFE0

Q41624982-0583EB75-4A22-40C8-BAF1-50CC61B60DC5

Q41624982-08FB8ABC-6155-4C73-82F3-213D27E838D8

Q41624982-1561FD56-197A-4EF2-89F8-62D340094B00

Q41624982-286B5EEB-DA82-4920-B71E-40559D6F9C99

Q41624982-2DBE9C33-2E0E-4FD8-AEF4-E7482CDB072A

Q41624982-475B97ED-961C-41B6-87A5-E55F9C782C57

Q41624982-5BC4A927-1618-4E1B-9F7E-B421EAFE6673

Q41624982-5BD4C80B-BA17-49AA-8153-A57ADB0E2488

Q41624982-6A962D6A-CE37-4835-870E-9149D3F508A3

P2888

Q41624982-B185DE37-BA87-4143-8FB1-DB4950E31247

P304

Q41624982-DF4243A4-DA14-42B2-83B8-6D2348D8DF8C

P31

Q41624982-02700274-68E6-46B1-B38B-2F857B13E03E

P356

Q41624982-4660F5A0-D0C7-41EB-BBB0-2FCB2E879312

P433

Q41624982-7A5C5340-1218-452C-94CD-AD348767667E

P478

Q41624982-F260FA61-88DF-4BD7-9353-7530968F105C

P50

Q41624982-13A50EFC-352C-4F21-BFFD-010CD81E64E2

Q41624982-5B9A625B-9C2D-4220-BF29-15098088683A

Q41624982-77BBBE44-24F7-42D0-8BB4-1A8758080D61

Q41624982-7C979BC2-D25B-4F54-988D-BD9885D9DDB0

Q41624982-80F2C479-13DE-4EBB-8EB9-963D50610EFB

Q41624982-89EE4094-B9C6-4E87-8619-D654EAFC5D1F

Q41624982-9AAEAAE8-154F-44E1-A86B-2B0E7462F338

Q41624982-9C601AE3-4B81-440B-A43C-E46444D3F25C

Q41624982-C3C553AE-F0D2-4643-883D-27FDB31A0608

Q41624982-D2F31EF5-69BC-439D-A67E-68DD291360C1

P577

Q41624982-15FBD429-5581-4DE7-BAB4-6A9D715597C0

P5875

Q41624982-D9DA67F9-45EE-4765-83F3-CAC06C367568

P698

Q41624982-7D8E3694-6680-45AA-B292-8A5447F15899

P356

S11523-014-0356-3

P1433

Targeted oncology

P1476

Prognostic significance of hos ...... treated with targeted therapy.

@en

P2093

Cinzia Ortega

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Francesco Massari

http://www.w3.org/2001/XMLSchema#string

Giovanni Muzzonigro

http://www.w3.org/2001/XMLSchema#string

Linda Cerbone

http://www.w3.org/2001/XMLSchema#string

Lisa Derosa

http://www.w3.org/2001/XMLSchema#string

Luciano Burattini

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Mimma Rizzo

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

Hallmarks of Cancer: The Next Generation

Cancer-related inflammation

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

The von Hippel-Lindau tumor suppressor gene and kidney cancer

Neutrophils in the activation and regulation of innate and adaptive immunity

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center.

P2888

s11523-014-0356-3

P304

517-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-014-0356-3

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Stefano Cascinu

Giuseppe Procopio

Sebastiano Buti

Alessandro Conti

Melissa Bersanelli

Rodolfo Montironi

P577

2015-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270516818

http://www.w3.org/2001/XMLSchema#string

P698

25559290

http://www.w3.org/2001/XMLSchema#string